Xeris Biopharma Holdings, Inc.
XERSXeris Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative therapies for patients with chronic endocrine and neurological diseases.
Earnings
Next report
Nov 5, 2026 (In 3 days)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Xeris Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative therapies for patients with chronic endocrine and neurological diseases. The company utilizes its proprietary XeriSol and XeriJect non-aqueous formulation technologies to create ready-to-use, room-temperature stable injectable medicines. Their core value proposition lies in improving patient outcomes by making previously difficult-to-inject treatments more convenient and accessible.
Xeris maintains a competitive edge through proprietary non-aqueous formulation platforms and orphan drug exclusivity for its rare disease portfolio.
FAQ
- What is Xeris Biopharma Holdings, Inc.'s market cap?
- Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $2.0B and trades on NASDAQ.
- What is Xeris Biopharma Holdings, Inc.'s revenue and profitability?
- Xeris Biopharma Holdings, Inc. generated $335.4M in trailing twelve-month revenue with a net loss of $17.2M, representing a net margin of -5.1%. Gross margin stands at 86.6%. The latest reported period is Q2 2026.
- Who are Xeris Biopharma Holdings, Inc.'s competitors?
- Xeris Biopharma Holdings, Inc.'s key competitors include Eton Pharmaceutcials, Inc. Common Stock, Corcept Therapeutics Inc., Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Xeris Biopharma Holdings, Inc. have?
- Xeris Biopharma Holdings, Inc.'s subsidiaries include Strongbridge Biopharma plc.
- Where is Xeris Biopharma Holdings, Inc. headquartered?
- Xeris Biopharma Holdings, Inc. is headquartered in United States of America and employs approximately 377 people. It has been publicly traded since 2018.
